Workflow
Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
Prnewswire·2025-09-17 13:00

药物疗效数据 - orforglipron在主要终点上降低A1C达2.2% 优于口服司美格鲁肽的1.4%降幅[1] - 最高剂量orforglipron组患者平均减重19.7磅（9.2%）[1]